Early CPAP in COVID-19 Patients With Respiratory Failure. A Prospective Cohort Study. (EC-COVID-PCS)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04323878|
Recruitment Status : Recruiting
First Posted : March 27, 2020
Last Update Posted : September 2, 2020
This cohort study aims at prospectively collecting detailed clinical information on patients positive to or suspected of COVID-19 visiting Italian emergency departments (EDs). The objectives of the study are:
- To monitor and describe the COVID-19 patients visiting Italian EDs.
- To assess the prognostic impact of demographics, clinical characteristics, risk factors and pre-existing diseases.
- To develop a predictive model, providing estimates of the prognosis using multiple relevant factors.
- To construct a detailed database to enable comparative effectiveness research (CER), with the goal of generating hypothesis of efficacy and effectiveness of treatments, therapies and interventions, in the management and treatment of COVID-19 patients.
|Condition or disease|
|Early CPAP Ventilation in COVID-19 Patients|
All the ED patients positive to or suspected of COVID-19 infection will be included in the study. Descriptive reports of the collected data will be produced regularly. Different levels of aggregation will be considered: single center, province, region. In addition to providing useful elements to describe the evolution of the epidemic, the results presented in these reports will provide an accurate clinical description of a large sample of COVID-19 patients.
The study data will be leveraged to identify the most important risk factors and clinical conditions to predict poor patient outcomes. The most relevant factors will be selected using state-of-the-art techniques.
These factors will be used as predictors in multivariable predictive models, which will be developed to estimate the expected prognosis of the patients. The study outcomes will be death or need of intubation within 7 days since ED arrival and 30-day mortality. Given the dichotomous nature of these variables, the models will be developed with logistic regression. The models will be first developed when the study will enroll the minimum number of necessary patients, and periodically updated. In this way, predictive tools capable of making accurate estimates of the prognosis of patients will be returned to the clinical practice as soon as possible.
The study will record the use of treatments and drugs, such as antivirals, ACE inhibitors and sartans, whose effect on COVID-19 patients is not yet clear and mostly based on small studies. The large cohort of patients will be used to perform CER analyses and evaluate the effect of these treatments on the prognosis of patients, with appropriate statistical methodology to account for the observational nature of the data. These results will be used to refine and improve the experimental design of this project.
|Study Type :||Observational|
|Estimated Enrollment :||3000 participants|
|Official Title:||EC-COVID-PCS - Early CPAP in COVID Patients With Respiratory Failure. A Prospective Cohort Study.|
|Actual Study Start Date :||June 1, 2020|
|Estimated Primary Completion Date :||October 5, 2020|
|Estimated Study Completion Date :||November 9, 2020|
- Death or need of intubation [ Time Frame: 7 days since ED arrival ]The study outcomes will be death or need of intubation within 7 days since ED arrival.
- 30-day mortality [ Time Frame: 30 days since ED arrival ]30-day mortality
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04323878
|Contact: Guido Bertolini, MD||+39 035 4535 313||Guido.firstname.lastname@example.org|
|Contact: Elena Garbero, M.Sc||+39 035 4535 313||Elena.email@example.com|
|Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico||Recruiting|
|Milan, Italy, 20122|
|Contact: Giorgio Costantino 02 99.95.99 firstname.lastname@example.org|
|Study Director:||Guido Bertolini, MD||Istituto di Ricerche Farmacologiche Mario Negri IRCCS|